ALNUTYCE

Live / Allowed — Fifth extension granted (statement of use) (as of 03 Oct 2026)

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 19 Apr 2023 filing date already counts against anyone who files later.

Record

Serial number
97896322
Mark type
Word mark
Filed
19 Apr 2023
Published for opposition
09 Jan 2024
Attorney of record
Marilyn F. Kelly

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Owner

Prosecution history

  • 03 Oct 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 03 Oct 2026 — SOU EXTENSION 5 GRANTED
  • 26 Aug 2026 — SOU EXTENSION 5 FILED
  • 03 Oct 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 26 Aug 2026 — SOU TEAS EXTENSION RECEIVED
  • 12 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 12 Feb 2026 — SOU EXTENSION 4 GRANTED
  • 12 Feb 2026 — SOU EXTENSION 4 FILED
  • 12 Feb 2026 — SOU TEAS EXTENSION RECEIVED
  • 27 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 26 Aug 2025 — SOU EXTENSION 3 GRANTED
  • 26 Aug 2025 — SOU EXTENSION 3 FILED
  • 26 Aug 2025 — SOU TEAS EXTENSION RECEIVED
  • 04 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 04 Mar 2025 — SOU EXTENSION 2 GRANTED

View this trademark record on Rightsy